* Palisade Bio Inc PALI.OQ PALI.O is expected to show no
change in quarterly revenue when it reports results on August 9
(estimated) for the period ending January 1 0001
*
* LSEG's mean analyst estimate for Palisade Bio Inc is for
a loss
of $2.93 per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Palisade
Bio Inc
is $33.75, above its last closing price of $3.61.
This summary was machine generated August 7 at 15:19 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)